Equities

Journey Medical Corp

DERM:NAQ

Journey Medical Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.20
  • Today's Change-0.03 / -0.57%
  • Shares traded71.89k
  • 1 Year change+20.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.

  • Revenue in USD (TTM)57.77m
  • Net income in USD-18.34m
  • Incorporated2014
  • Employees58.00
  • Location
    Journey Medical Corp9237 E Via De Ventura Blvd.Suite 105, Suite 105SCOTTSDALE 85258United StatesUSA
  • Phone+1 (480) 434-6670
  • Fax+1 (302) 531-3150
  • Websitehttps://journeymedicalcorp.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aadi Bioscience Inc25.07m-61.69m54.72m53.00--0.7935--2.18-2.29-2.290.92852.800.22250.6964.09281,685.40-54.75-50.25-65.27-56.1587.39---246.06-473.974.54--0.00--60.063.85-8.68--153.54--
OptiNose Inc75.67m-31.15m55.34m132.00------0.7313-0.2216-0.22160.5416-0.27250.65120.76592.96573,272.80-26.80-48.25---98.9590.2186.96-41.16-131.660.7198-1.611.48---6.9358.6452.58---27.96--
bluebird bio Inc53.12m-300.52m58.76m375.00------1.11-1.84-1.840.3039-0.02980.09852.034.42141,653.30-55.72-34.75-96.37-40.84-43.49-124.35-565.74-5,770.410.3272-13.371.03--720.04-11.588.00---30.47--
Cellectar Biosciences Inc0.00-48.74m63.28m20.00--12.33-----2.51-2.510.000.38390.00----0.00-271.59-83.69-682.65-99.80-----------41.970.00-------32.80--17.55--
Procaps Group SA414.10m52.20m64.48m5.50k1.101.640.92550.15570.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Hongchang International Co Ltd5.42m-208.79k66.15m8.00--1.63--12.21-0.0004-0.00040.01040.07840.09915.5037.20---0.2731-7.98-0.2965-10.944.5111.47-2.76-64.884.64--0.3169--3,289.22---42.63------
Global Pharmatech Inc.3.18m-2.24m67.19m217.00--0.4959--21.13-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
CASI Pharmaceuticals Inc22.06m-30.97m70.49m176.00--5.09--3.20-2.23-2.231.591.030.320.92652.03125,312.50-43.04-34.75-66.19-46.9154.3155.98-134.50-153.722.32--0.58---21.41--34.27--14.65--
Rockwell Medical Inc98.92m-1.24m75.30m237.00--2.5852.810.7613-0.0496-0.04963.230.90151.8014.4510.84417,371.30-2.25-46.29-3.34-65.3816.914.66-1.25-36.512.000.31940.2654--14.845.6954.82--76.21--
Journey Medical Corp57.77m-18.34m77.87m58.00--9.92--1.35-0.9276-0.92762.930.52710.8892.166.19996,051.80-28.22---76.21--57.32---31.74--1.03-13.650.6582--7.48--87.00------
I-Mab ADR-100.00bn-100.00bn79.27m220.00--0.3373----------2.91-----------35.51---41.43-------509.54----0.00--111.86-13.6544.45---5.95--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.37m35.00391.37348.44--35.440.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
Assertio Holdings Inc125.76m-68.49m90.57m53.00--0.6941--0.7202-0.7212-0.72121.321.370.38340.90522.342,372,887.00-20.88-21.51-30.33-32.0570.3188.68-54.46-62.101.57--0.2293---2.67-13.38-402.80---28.25--
Data as of Nov 21 2024. Currency figures normalised to Journey Medical Corp's reporting currency: US Dollar USD

Institutional shareholders

11.50%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2024320.53k2.18%
Cambridge Investment Research Advisors, Inc.as of 30 Sep 2024314.45k2.14%
Renaissance Technologies LLCas of 30 Sep 2024268.20k1.82%
American Money Management Corp.as of 30 Sep 2024180.00k1.22%
PVG Asset Management Corp.as of 30 Jun 2024158.54k1.08%
Envestnet Asset Management, Inc.as of 30 Sep 2024109.59k0.74%
Geode Capital Management LLCas of 30 Sep 2024108.44k0.74%
Rosalind Advisors, Inc.as of 30 Sep 2024105.92k0.72%
Neuberger Berman Investment Advisers LLCas of 30 Sep 202464.39k0.44%
Geneos Wealth Management, Inc.as of 30 Sep 202463.28k0.43%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.